Course Information

Release date: May 29, 2026
Expiration date: May 29, 2027
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.

PROGRAM OVERVIEW

Blood eosinophil assessment is now a central component of chronic obstructive pulmonary disease (COPD) evaluation and treatment selection within the Global Initiative for Obstructive Lung Disease (GOLD) framework. However, real-world implementation remains inconsistent due to uncertainty surrounding timing, interpretation, and repeat measurement. This engaging program equips clinicians with practical, case-based strategies to confidently interpret biomarkers such as blood eosinophil levels and apply evolving GOLD recommendations, including the use of biologics in appropriate patients, to deliver more precise, personalized COPD management.

Learning Objective

TARGET AUDIENCE

This educational activity is designed for pulmonologists and internal medicine physicians involved in the management of patients with COPD.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

Discuss challenges and solutions for the effective use of biomarker assessment in the management of COPD

Faculty Information and Disclosures

FACULTY CHAIR

Nick Hanania, MD, MS

Director, Airways Clinical Research Center

Brown Foundation Professor of Medicine

Clinical Science Representative, Faculty Senate

Baylor College of Medicine

Chief, Section of Pulmonary, Critical Care and Sleep Medicine

Ben Taub Hospital

Houston, Texas

FACULTY PANEL

Diego J. Maselli, MD, FCCP, ATSF

Professor of Medicine and Chief

Division of Pulmonary Diseases & Critical Care

University of Texas Health, San Antonio

San Antonio, Texas

Dave Singh, MD, FERS, FBPhS

Professor of Clinical Pharmacology and Respiratory Medicine

University of Manchester

Medical Director, Medicines Evaluation Unit, An IQVIA Business

Manchester, United Kingdom

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Nick Hanania, MD, MS
Advisor: Amgen, AstraZeneca, Chiesi, Connect Biopharma, Genentech, GSK, Regeneron/Sanofi
Contracted Research: Amgen, AstraZeneca, Chiesi, Genentech, GSK, Regeneron/Sanofi

Diego J. Maselli, MD, FCCP, ATSF 
Consultant & Speaker: Amgen, AstraZeneca, GSK, Insmed, Regeneron/Sanofi

Dave Singh, MD , FERS, FBPhS
Consultant: AstraZeneca, Chiesi, Cipla, CSL Behring, EpiEndo, Genentech, Glenmark, Gossamer Bio, GSK, Kinaset Therapeutics, Menarini, Novartis, Orion, Pulmatrix, Sanofi, Teva, Theravance Biopharma, Verona Pharma

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of May 29, 2026 through May 29, 2027, participants must:

Read the learning objectives
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 33% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Internet: Stable connection
Operating Systems: Windows 10/macOS 10.14 or later recommended
Web Browser: Latest versions of Google Chrome, Microsoft Edge, or Safari recommended (other modern browsers also supported)
Plug-ins: No plug-ins required

For optimal performance and security, ensure your browser is up to date and avoid using unsupported or outdated versions.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: May 29, 2026Expiration date: May 29, 2027Estimated time to complete activity: 15 minutes

Advancing COPD Care Through Data-Driven Education and Precision Medicine: The Use of Biomarkers in COPD Management